patiromer (Veltassa)
Jump to navigation
Jump to search
Indications
- hyperkalemia (FDA-approved Oct 2015)
- useful in patients with chronic renal failure on ACE inhibitors, ARBs or other RAAS Inhibitor (spironolactone)
Contraindications
- not appropriate for rapid correction of severe hyperkalemia[2]
Adverse effects
Mechanism of action
More general terms
References
- ↑ Weir MR et al Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. Nov 21, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25415805 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1410853
Ingelfinger JR A New Era for the Treatment of Hyperkalemia? N Engl J Med. Nov 21, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25415806 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1414112 - ↑ 2.0 2.1 2.2 Stiles S FDA Approves Potassium-Binder Patiromer (Veltassa), New Option for Patients on RAAS Inhibitor-Treated Patients Medscape Oncology. October 21, 2015 http://www.medscape.com/viewarticle/853049
FDA News Release. October 21, 2015 FDA approves new drug to treat hyperkalemia http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468546.htm - ↑ Lou N Patiromer Helps CKD Patients Stay on Spironolactone
Now the question is: Can outcomes can be improved? MedPage Today. September 15, 2019 https://www.medpagetoday.com/cardiology/hypertension/82166
Agarwal R, Rossignol P, Romero A et al Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019. Sept 15 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31533906 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32135-X/fulltext
Agarwal R, Rossignol P, Garza D et a; Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. Am J Nephrol. 2018;48(3):172-180. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30176673 Free PMC Article - ↑ Di Palo K, Sinnett MJ, Goriacko P Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting. JAMA Netw Open. 2022;5(1):e2145236 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35080601 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788445